UPPSALA, SWEDEN - LIDDS AB (publ) announces today that the company's CEO Anders Månsson and CSO Matthew Lindon will participate in the Nordic Life Science Days on 28 and 29 September 2022.

LIDDS’ CEO Anders Månsson and CSO Matthew Lindon participate in the Nordic Life Science Days which is held in Malmö for the first time since 2019.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: nina.herne@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS participates in Nordic Life Science Days 2022

© Modular Finance, source Nordic Press Releases